Transgene names chief technical director (CTO) to feed future innovations 01.04.25

Dr. Simone Steiner will focus on improving individualized immunotherapy manufacturing processes Myvac® platform

Strasbourg, France, April 1, 2025, 17:45 CET – Transgene (Euronext Paris: TNG), A biotechnological company that designs and develops virus -based cancer -based immunotherapies is delighted announces the appointment of Simone Steiner, PhD, as the main technical director (CTO), actually immediately.

Dr. Steiner will be responsible for the manufacture and development of processes for the innovative pipeline of the transgene immunotherapy product. It will continue to lead the optimization of the manufacturing process for individualized neo -antigen therapeutic vaccines. Simone Steiner will also be involved in developing potential candidates based on Myvac® The platform and in a second planned clinical study to start in the fourth quarter 2025.

Dr. Steiner reports to the President and CEO, Alessandro Riva, and is a member of the Executive Committee.

Dr. Alessandro Riva, MD, president and CEO of Transgenecommented: “On behalf of the whole team, I am delighted to greet Simone as a technical chief (CTO). It brings a vast expertise in technical innovation and in developing development technologies, which perfectly align with the mission to push the borders of the innovative treatment of cancer. Myvac® therapeutic vaccines and off-raft products which will significantly benefit the portfolio of transgene assets. “

Dr. Simone Steiner, chief technical officer, added: “I look forward to contributing to the acceleration of transgene programs by using the latest technologies. With the clinical proof of the principle for the individualized TG4050 cancer vaccine, I am pleased to help impulse the manufacture before and processes in potential pivotal studies and start preparing the production on a commercial scale.
Transgene stands out in the biotechnology space due to its advanced expertise in viral vectors, I look forward to working with the team while working to bring a new generation of cancer treatments in patients. “

Biography Dr. Simone Steiner, PhD

Simone Steiner, PhD, has almost 20 years of pharmaceutical experience within the preclinic, clinical and marketing in organizations, from startups to multinational pharmaceutical companies.

Before transgene, she was the technical operating director (CTOO) at T-Knife Therapeutics, a biopharmaceutical company that develops T (TCR-T) receptor (TCR) (TCR-T) therapies to fight cancer, where it has its technical development and manufacture.

Before her time at T-Cuțit, Dr. Steiner was the head of technical development and production in Tigen, in Switzerland, where she managed the optimization of manufacturing processes and the creation of new biopharmaceuticals.

Dr. Steiner’s career also includes over ten years in Novartis, where he has expanded his expertise in technical operations and manufacturing, contributing to large-scale production strategies for innovative therapies.

With a strong basis in the latest technologies and their implications for health, Dr. Steiner is recognized for combining scientific accuracy with strategic management to advance the therapeutic development and manufacture initiatives.

She has held the position of scientific counselor in Negociumai, an innovative platform that uses the latest generation to make the relationship between advanced therapy drug developers and contract producers.

Dr. Steiner owns a master’s degree in biochemistry, a doctorate from Eth Zurich and has completed a postdoctoral scholarship at the University of Alberta, Canada.

***

About transgene

Transgene (Euronext: TNG) is a biotechnology company focused on the design and development of the immunotherapy for cancer treatment. The clinical stage programs of the company consist of a portfolio of viral immunoterapeutic based on vector. TG4050, the first individualized therapeutic vaccine based on MyVac® The platform is the main assets of the company, with the proof of the principle in patients in the adjuvant treatment of head and neck. The portfolio also includes other viral immunotherapies based on Vector: TG4001 for the treatment of HPV positive cancer, as well as BT-001 and TG6050, two oncolytic viruses based on the viral spine Inv.IO®. The company also makes innovative discoveries and preclinical works, aimed at developing new viral vector -based ways.
With transgene MyVac® The platform, therapeutic vaccination enters the field of precision drug with a new immunotherapy that is completely adapted to each individual. Myvac® The approach allows the generation of a virus -based immunotherapy that encodes the patient -specific mutations identified and selected by the artificial intelligence capacities provided by its NEC partner.
With his platform owner Invr.IO®, Transgene is based on its viral vector engineering expertise to design a new generation of multifunctional oncolytic viruses.
Additional transgene information is available at: www.transgene.fr

Follow -ne on social media: X (former twitter): @Transgenesa – LinkedIn: @Transgene

Contacts

TRANSGENE CONTACT:	Contact transgene media:
Mediate:	Medistrava
Caroline Tosch	Frazer Hall/Sylvie Berrebi
Corporate communication manager	+ 44 (0) 203 928 6900
+33 (0) 3 68 33 27 38	[email protected]
[email protected]

Lucie Larguier
Chief Financial Officer
Nadege Bartoli
IR analyst and financial communications officer
+33 (0) 3 88 27 91 03/00
[email protected]

renunciation

This press release contains prospective statements, which are subject to numerous risks and uncertainties, which could determine the real results to differ significantly from the anticipated ones. The occurrence of any of these risks could have a significant negative result for activities, perspectives, financial situation, results, agreement of the regulatory authorities with developmental phases and development. The ability of the company to market its products depends, but it is not limited to the following factors: positive pre-clinical data cannot be predictive of human clinical results, the success of clinical studies, the ability to obtain financing and/or partnerships for the manufacture of products, the development and marketing approval by the government regulatory authorities. For a discussion of the risks and uncertainties that could determine the real results of the company, the financial status, performance or achievements to differ from those contained in prospective statements, please consult the risk factors (“Risque invoices”) in the universal registration document, available on the IMF website (or on the transgene site (www.transgene.FR). these advances-loo

20250401_Transgene_cto_appointment_en